Indian clinical practice consensus guidelines for the management of nasopharyngeal cancer

• Published in: Indian journal of cancer Vol. 57; no. 5; pp. 9 - 11
• Main Authors: Gairola, Munish, Prabhash, Kumar, Babu, Govind, Chaturvedi, Pankaj, Kuriakose, Moni, Birur, Praveen, Anand, Anil, Kaushal, Ashish, Mahajan, Abhishek, Syiemlieh, Judita, Singhal, Manish, Ramachandra, Prakash, Goyal, Sumit, John, Subashini, Nayyar, Rohit, Patil, Vijay, Rao, Vishal, Roshan, Vikas, Rath, G
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.02.2020; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Cancer; Cancer therapies; Carboplatin; CAT scans; Cetuximab; Chemotherapy; Diagnostic imaging; Fiber optic equipment; Head & neck cancer; Medical examination; Monoclonal antibodies; Nasopharyngeal cancer; Neck; Oral cancer; Practice guidelines (Medicine); Radiation therapy; Targeted cancer therapy; Throat cancer; Tomography; Workflow software; India; Sri Lanka
• ISSN: 0019-509X; 1998-4774
• DOI: 10.4103/0019-509X.278974

[...]concurrent CT/RT followed by adjuvant CT should be the standard of care for advanced nasopharyngeal carcinoma. High-risk sites: typically, 70–70.2 Gy (1.8–2.0 Gy/fraction); daily Monday–Friday in 7 weeks and low-to-intermediate risk sites: 44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) (EL 2; Grade B)Concurrent CTRT plus nimotuzumab (EL 1; Grade A)/cetuximab (EL1; Grade B) can be recommended in patients with advanced nasopharyngeal carcinoma[13],[14]Induction CT + Intensity-modulated radiation therapy + nimotuzumab can be an option in patients with advanced nasopharyngeal carcinoma. The task force members have taken this educational initiative of developing India specific consensus guidelines for management of head and neck cancer under its ambit.